Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Estrella Immunopharma ( (ESLA) ) has provided an update.
On January 5, 2026, Estrella Immunopharma entered into a securities purchase agreement with a single healthcare-focused institutional investor for a registered direct offering of common stock and pre-funded warrants, alongside a concurrent private placement of common stock purchase warrants, all priced at-the-market under Nasdaq rules. The offerings, which closed on January 6, 2026, involved the sale of 5,063,290 units (or pre-funded units) and 7,594,935 PIPE warrants at a unit price of about $1.58, generating approximately $8.0 million in gross proceeds before fees, which the company plans to use for general corporate purposes and working capital; the structure adds potential future dilution via warrant exercises while bolstering Estrella’s cash position as it advances its cell therapy pipeline.
The most recent analyst rating on (ESLA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Estrella Immunopharma stock, see the ESLA Stock Forecast page.
More about Estrella Immunopharma
Estrella Immunopharma, Inc., based in Emeryville, California, is a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS T-cell therapies aimed at treating cancers and autoimmune diseases. Its lead product candidates, EB103 and EB104, leverage Eureka’s ARTEMIS technology to target B-cell malignancies, including leukemias and lymphomas expressing CD19 and CD22.
Average Trading Volume: 280,308
Technical Sentiment Signal: Sell
Current Market Cap: $50.23M
For a thorough assessment of ESLA stock, go to TipRanks’ Stock Analysis page.